v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash Flows from Operating activities:    
Net income (loss) $ 55,385,211 $ (39,203,970)
Net income (loss) from discontinued operations 73,219,707 (23,242,809)
Net loss from continuing operations (17,834,496) (15,961,161)
Adjustments to reconcile net loss to net cash    
Stock-based compensation expense 9,235,377 3,725,484
Depreciation expense 122,916 123,253
Loss on settlement/conversion of debt to equity 5,193,382 0
Interest and dividend income (559,476) 0
Investment in other entities - Related Parties, net 84,063 409,268
Issuance of common shares for consulting services 83,969 143,575
Allowance for losses on note receivable 280,000 0
Unrealized gain on short-term investments   45,514
Change in current assets and liabilities:    
Interest receivable 0 (85,991)
Accounts receivable - related party (1,970,096) 8,457,521
Prepaid expenses and other current assets (2,015,109) 69,667
Trade and non-trade payable (2,989,695) 4,100,581
Accrued expenses (608,180) 544,856
Accrued interest (13,616) 44,969
Operating lease assets and liabilities, net 81,863 846
Operating lease assets and liabilities, net - related party 497,253 373,419
Cash (used in) provided by operating activities (10,411,845) 1,991,801
Cash Flows from Investing activities:    
Purchase of property and equipment, net of capitalized interest income and (expense) (37,297) 230,932
Purchase of certificate of deposit (5,000,000) 0
Proceeds from short-term investments, net 0 715,036
Purchases of short-term investments/securities (34,323,318) 0
Cash (used in) provided by investing activities (39,360,615) 945,968
Cash Flows from Financing activities:    
Proceeds from equity offering, net of issuance costs 68,123,675 0
Proceeds from long-term debt 965,286 0
Exercise of warrants for common stock 7,525,000 0
Proceeds from the exercise of stock options and warrants   189,239
Proceeds received from other financing obligation 8,071,908 2,484,694
Repayments of other financing obligation (3,412,948) (7,025,901)
Cash provided by (used in) financing activities 81,272,921 (4,351,968)
Net change in cash, cash equivalents and restricted cash from continuing operations 31,500,460 (1,414,199)
Cash flows from discontinued operations:    
Net cash flow used in discontinued operating activities (7,370,831) (23,235,014)
Net cash flow used in discontinued investing activities (3,825,518) (126,346,329)
Net cash flow used in discontinued financing activities 13,475,625 150,031,311
Net change in cash and cash equivalents, discontinued operations 2,279,276 449,968
Cash and cash equivalents, including discontinued operations, beginning of year 4,113,329 5,077,560
Cash and cash equivalents, including discontinued operations, end of year 37,893,065 4,113,329
Less: Cash and cash equivalents at end of period discontinued operations 5,810,379 3,531,103
Cash, cash equivalents, and Restricted Cash 32,082,686 582,226
SUPPLEMENTAL CASH FLOW INFORMATION    
Exercise of cashless common stock options and warrants 59 87
Dividend-in-kind of Novustera, Inc. common stock to shareholders 0 1,361,788
Acquisition of assets through operating leases - related party 0 1,897,736
Common stock issued to settle accounts payable and accrued expenses 6,309,329 1,116,100
Common stock issued to settle debt $ 6,413,307 $ 0